What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
"We are encouraged by this data and the potential benefit that trem-cel in combination with Mylotarg may offer to patients in a disease that has extremely poor outcomes even after transplant," said Eyal Attar, Vor Bio's Chief Medical Officer. "With this data, we plan to explore a registrational trial while we continue to pursue other synergistic opportunities for Vor Bio's platform such as VCAR33ALLO and VADC45." Thursday, Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
周四，Vor Biopharma Inc.（纳斯达克股票代码：VOR）公布了其正在进行的1/2期VBP101 研究的新临床数据，该研究针对的是复发/难治性急性髓系白血病（AML）患者，随后接受mylotarg治疗。
Pfizer Inc's (NYSE:PFE) Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients two years and older.
辉瑞公司（纽约证券交易所代码：PFE）的Mylotarg适用于成人新诊断的CD33阳性急性髓细胞白血病，以及成人和两岁及以上儿童患者的复发或难治性急性髓细胞白血病CD33阳性急性髓系白血病。
The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.
数据显示了可靠的移植，可以屏蔽Mylotarg的靶向毒性，扩大了Mylotarg的治疗窗口，并有早期的患者获益证据。
"We are encouraged by this data and the potential benefit that trem-cel in combination with Mylotarg may offer to patients in a disease that has extremely poor outcomes even after transplant," said Eyal Attar, Vor Bio's Chief Medical Officer. "With this data, we plan to explore a registrational trial while we continue to pursue other synergistic opportunities for Vor Bio's platform such as VCAR33ALLO and VADC45."
Vor Bio首席医学官埃亚尔·阿塔尔表示：“这些数据以及trem-cel与Mylotarg联合使用可能为即使在移植后预后极差的疾病的患者带来的潜在益处令我们感到鼓舞。”“利用这些数据，我们计划探索注册试验，同时继续为Vor Bio的平台（例如 VCAR33ALLO 和 VADC45）寻找其他协同机会。”
The data released included 18 patients treated with trem-cel of which ten had received Mylotarg as of the data cut-off date of July 19, 2024. The data demonstrated:
公布的数据包括18名接受trem-cel治疗的患者，截至2024年7月19日的数据截止日期，其中10名已接受Mylotarg治疗。数据表明：
- Reliable engraftment, with 100% of patients achieving primary neutrophil engraftment (median 9 days) and robust platelet recovery (median 16.5 days).
- Shielding of the blood system, with maintained neutrophil and platelet counts across multiple Mylotarg doses of 0.5, 1, and 2 mg/m2.
- Early evidence suggests patient benefit as measured by relapse-free survival compared to published high-risk AML comparators.
- 可靠的植入，100% 的患者实现了原发性中性粒细胞移植（中位数 9 天）和稳健的血小板恢复（中位数 16.5 天）。
- 保护血液系统，在多次 Mylotarg 剂量分别为 0.5、1 和 2 mg/m2 时保持中性粒细胞和血小板计数。
- 早期证据表明，与已公布的高危急性髓细胞白血病比较相比，患者受益是通过无复发存活率来衡量的。
Vor Bio plans to approach the FDA to discuss a pivotal trial design for trem-cel + Mylotarg by around the end of the year.
Vor Bio计划在今年年底前后与美国食品药品管理局接触，讨论trem-cel + Mylotarg的关键试验设计。
Vor Bio announced a new preclinical asset, VADC45, which has several potential opportunities in oncology, gene therapy, and autoimmune disorders.
Vor Bio宣布了一项新的临床前资产 VADC45，该资产在肿瘤学、基因疗法和自身免疫性疾病方面具有多种潜在机会。
The company said cash, cash equivalents, and marketable securities were $85.9 million as of June 30, 2024, projected to fund operations into the second half of 2025.
该公司表示，截至2024年6月30日，现金、现金等价物和有价证券为8,590万美元，预计将为2025年下半年的运营提供资金。
Price Action: VOR stock is up 28.5%at $1.06 at last check Friday.
价格走势：周五最后一次查看时，VOR股价上涨28.5％，至1.06美元。
Photo via Shutterstock
照片来自 Shutterstock
- GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug.
- 葛兰素史克的哮喘药物达到了针对吸烟者肺部患者的3期研究的主要目标，准备与安进/阿斯利康的药物竞争。
